Simpson Thacher represented the underwriters, led by Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, in a U.S. registered public offering by AstraZeneca PLC and its wholly owned subsidiary, AstraZeneca Finance LLC, of $7 billion of Senior Notes with maturities ranging between one and thirty years. The offering closed on May 28, 2021, with the net proceeds to be used to fund a portion of the purchase price for the acquisition of Alexion Pharmaceuticals Inc., to pay or refinance a portion of Alexion’s indebtedness and to pay related fees and expenses, with any remaining proceeds being used for general corporate purposes.
AstraZeneca is a global, science-led, patient-focused pharmaceutical business that focuses on the discovery, development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca’s ordinary shares are admitted to trading on the London Stock Exchange and its American Depositary Shares are listed on the New York Stock Exchange, both under the symbol “AZN.”
The Simpson Thacher team included Mark Brod, John C. Ericson, Srishti Gupta and Amanda Obi (Capital Markets); Jonathan Cantor and Zachary Fialkow (Tax); Vanessa Burrows (Healthcare); Bobbie Burrows and Alysha Sekhon (IP); and Jennie Getsin (FINRA and Blue Sky).